Study to Evaluate Impact® as Support to Anti PD1 or Anti PD1 Based Regimen Treatment in Patients With Inoperable Locally Advanced or Metastatic Melanoma

This study tests a nutritional supplement called Impact — which contains specific nutrients thought to support the immune system — alongside standard immunotherapy (anti-PD-1 drugs) for people with advanced melanoma (skin cancer that has spread or cannot be removed). The goal is to see whether the supplement improves treatment outcomes. **You may be eligible if:** - You are 18 or older - You have been confirmed by biopsy to have stage III (unresectable) or stage IV melanoma - You are about to start treatment with an anti-PD-1 immunotherapy drug (alone or in combination) - Your PD-L1 status has been assessed as part of standard care **You may NOT be eligible if:** - Your melanoma is at an earlier stage that can be surgically removed - You have already received immunotherapy for your melanoma - You have serious autoimmune disease or other conditions that make immunotherapy unsafe - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.